TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,945,624 | -36.2% | 1,671,770 | +9.6% | 0.09% | -34.1% |
| Q2 2023 | $23,420,928 | -29.0% | 1,524,800 | +4.0% | 0.14% | -33.2% |
| Q1 2023 | $32,964,762 | +77.3% | 1,465,752 | +65.8% | 0.20% | +60.3% |
| Q4 2022 | $18,596,030 | +3.7% | 884,262 | +21.4% | 0.13% | -11.3% |
| Q3 2022 | $17,941,000 | +32.7% | 728,114 | +30.5% | 0.14% | +35.2% |
| Q2 2022 | $13,518,000 | -43.3% | 557,903 | -39.7% | 0.10% | -34.4% |
| Q1 2022 | $23,849,000 | -18.2% | 925,444 | -1.5% | 0.16% | -17.9% |
| Q4 2021 | $29,149,000 | +16.4% | 939,092 | -9.0% | 0.20% | +15.4% |
| Q3 2021 | $25,036,000 | +116.9% | 1,032,398 | +30.5% | 0.17% | +116.7% |
| Q2 2021 | $11,540,000 | -27.9% | 790,931 | +23.4% | 0.08% | -36.6% |
| Q1 2021 | $16,010,000 | -9.1% | 641,172 | -0.8% | 0.12% | -20.1% |
| Q4 2020 | $17,608,000 | – | 646,050 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |